
Commentary|Videos|May 22, 2025
Breaking Down Treatment Expectations With Revumenib in Pediatric KMT2A+ R/R Acute Leukemia
Author(s)Lia Gore, MD, Sarah K. Tasian, MD
Fact checked by: Chris Ryan
Lia Gore, MD, and Sarah K. Tasian, MD, discuss treatment expectations with revumenib in pediatric relapsed/refractory acute leukemia.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
4
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
5






























































